eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica Supplement
Current supplement Archive Acta Ophthalmologica Polonica
1-2/2004
vol. 106
 
Share:
Share:
abstract:
Original paper

Timolol 0,5%/ dorzolamide 2% fixed combination versus timolol 0,5%/ pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients

Jakub J. Kałużny
1
,
Jerzy Szaflik
2
,
Krystyna Czechowicz-Janicka
3
,
Józef Kałużny
1
,
Ali­cja Orzał­kie­wi­cz
1
,
Anna Zaleska-Żmijewska
2
,
Małgorzata Krajewska
3
,
Je­anet­te A. Stewar
4
,
Jes­si­ca N. Leech
4
,
Wi­liam C. Stewar
4, 5

  1. Z Kliniki Okulistyki Akademii Medycznej im. Ludwika Rydygiera w Bydgoszczy
  2. Z Samodzielnego Publicznego Klinicznego Szpitala Okulistycznego w Warszawie
  3. Z Centrum Medycznego Kształcenia Podyplomowego w Warszawie
  4. Pharmaceutical Research Network, Limited Liability Company, Charleston, South Carolina, USA
  5. Department of Ophthalmology, University of South Carolina, Columbia, South Carolina, USA
KLINIKA OCZNA 2004, Supl. 1-2: S241–S242
Online publish date: 2022/12/30
View full text Get citation
 
Purpose
To establish the efficacy and safety of timolol 0,5% / dorzolamide 2% fixed combination versus timolol 0,5% / pilocarpine 2% fixed combination, each given twice daily, in primary open-angle glaucoma and ocular hypertensive patients.

Material and methods
In this prospective, multicentred, double-masked trial, 37 patients were treated twice daily with timolol for 4 weeks. Then, they were randomized to one of the treatment medications for 6 weeks, after which they were treated with timolol again for 2 weeks before placed on the opposite treatment medication for 6 weeks.

Results
A total of 36 patients completed the trial. The mean baseline intraocular pressure (IOP) was 22,3± 3,7 mmHg. Following 6 weeks of treatment, the mean decrease of IOP was 18,0± 2,2 mmHg for timolol / dorzolamide combination and 17,4± 2,0 for timolol / pilocarpine combination. The mean diurnal curve IOP was 18,1± 2,2 mmHg for timolol / dorzolamide group and 16,7 ± 1,9 mmHg for timolol / pilocarpine group. These differences were statistically significant. Statistically more patients reported ocular pain and diminished vision during use of the timolol / pilocarpine combination.

Conclusions
This study suggest that timolol 0,5% / pilocarpine 2% fixed combination can provide at least similar efficacious reduction in IOP as timolol 0,5 % / dorzolamide 2% fixed combination in patients with primary open-angle glaucoma and ocular hypertension.

keywords:

open angle glaucoma, timolol, dorzolamide, pilokarpine

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.